Sugi Predict

Sugi Predict / Compounds / SCHEMBL2648754

SCHEMBL2648754

SCHEMBL2648754

CC(=O)Nc1ccc(I)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.57
▸ CA2 P00918 2/20 0.57
▸ CA9 Q16790 2/20 0.57
▸ HSD17B10 Q99714 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ RAB9A P51151 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ MAP2K1 Q02750 1/20 0.44
▸ ROCK2 O75116 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ PDE3B Q13370 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24481154 0.87 KDM4E (0.60) CA1CA2CA9HSD17B10KDM4E
SCHEMBL4801242 0.85 ALDH1A1 (0.58) CA1CA2CA9HSD17B10KDM4E
SCHEMBL9835469 0.83 MAP2K1 (0.46) CA1CA2CA9HSD17B10KDM4E
SCHEMBL18579148 0.83 MAP2K1 (0.49) HSD17B10KDM4ERAB9AALDH1A1NPC1
SCHEMBL11420542 0.82 ALDH1A1 (0.48) CA1CA2CA9KDM4ERAB9A
SCHEMBL10852754 0.81 CA1 (0.60) CA1CA2CA9HSD17B10KDM4E
SCHEMBL9400181 0.81 RAB9A (0.63) CA1CA2CA9HSD17B10KDM4E
SCHEMBL4311940 0.81 KDM4E (0.66) CA1CA2CA9HSD17B10KDM4E
SCHEMBL29822237 0.81 KDM4E (0.66) CA1CA2CA9HSD17B10KDM4E
SCHEMBL115706 0.79 CA1 (0.63) CA1CA2CA9HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 — — US disclosed
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 — — US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 — — US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 — — US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 — — US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 — — US disclosed
WO-2007007886-A1 AN OXIME DERIVATIVE AND PREPARATIONS THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-18 — — WO disclosed
CN-1209362-C Tetrazolyl-phenyl acetamide glucokinase activators HOFFMANN LA ROCHE (CH) 2005-07-06 — — CN disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 — — US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 — — US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 — — US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed
WO-2002014312-A1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-21 — — WO disclosed
EP-0409413-B1 Diaryl ether heterocycles ICI PLC (GB) 1994-08-03 — — EP disclosed
US-5208259-A Lipoxygenase enzyme inhibitors IMPERIAL CHEMICAL INDUSTRIES (GB) 1993-05-04 — — US disclosed
EP-0409413-A2 Diaryl ether heterocycles IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-01-23 — — EP disclosed
EP-0376103-A1 A 2-acylamino-5-halogenated-cinnamic acid derivative and method for its production Nippon Kayaku Kabushiki Kaisha (JP) 1990-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 CA1 1283/4885CA2 289/4885CA9 1011/4885
US-20080132479-A1 Oxime Derivative and Preparations Thereof GCK, KHK, GCKR CA1 1515/4885CA2 455/4885CA9 774/4885
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF GCK, KHK, GCKR CA1 1515/4885CA2 455/4885CA9 774/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 CA1 1283/4885CA2 289/4885CA9 1011/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL CA1 972/4885CA2 180/4885CA9 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.